Showing results (31-40 of 49) with videos related to
Sort By:
Pageof 5
Cell Reports. Medicine|February 18, 2026
Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancerZecheng Yang, Madelaine S Theardy, Shuaitong Chen, et al.JCI Insight|September 27, 2019
YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinomaBo Tu, Jun Yao, Sammy Ferri-Borgogno, et al.Journal of the National Cancer Institute|May 24, 2014
Overactivated neddylation pathway as a therapeutic target in lung cancerLihui Li, Mingsong Wang, Guangyang Yu, et al.Cancer Research|December 2, 2025
GFER Represents a Target for Dual Disruption of Redox Homeostasis and Reactivation of the Immune Response in Pancreatic AdenocarcinomaZiheng Chen, I-Lin Ho, Jintan Liu, et al.Nature Communications|April 17, 2023
Ether phospholipids are required for mitochondrial reactive oxygen species homeostasisZiheng Chen, I-Lin Ho, Melinda Soeung, et al.Cell Reports. Medicine|July 27, 2025
Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancersMadelaine S Theardy, Mitsunobu Takeda, Alexey Sorokin, et al.Biorxiv : the Preprint Server for Biology|August 30, 2024
Therapeutic targeting of Syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancersMitsunobu Takeda, Madelaine S Theardy, Alexey Sorokin, et al.Nature Communications|May 11, 2026
All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancerChing-Fei Li, Yongkun Wei, Heng-Huan Lee, et al.Cancer Research|March 5, 2015
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancerPiergiorgio Pettazzoni, Andrea Viale, Parantu Shah, et al.Cell|June 24, 2014
Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancerAvnish Kapoor, Wantong Yao, Haoqiang Ying, et al.Pageof 5